ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

azvudine

Also written as “Azvudine tablets(FNC) and Dolutegravir Sodium Tablets (DTG)”, “Azvudine tablets(FNC) and Itraconazole Capsules (ICZ)” and “Azvudine tablets(FNC) and Rifampicin Capsules (RIF)”.

Its studies are mostly in COVID-19 · Renal Insufficiency, led by 2 companies.

Drug pageAzvudine: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since May 8, 202510 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Henan Genuine Biotechits history only81 open or runningphase 1since May 8, 2025May 8, 2025none ahead
Fosun Pharma20 open or runningphase 3since Nov 30, 2022Nov 30, 2022none ahead

Also a collaborator on its studies: HeNan Sincere Biotech.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Fosun Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 30, 2022First study: phase 3 study in COVID-19First studyNCT05633433 · 1,550 enrolled · Malaysia, Philippines
  2. Jan 10, 2023Phase 2 study in COVID-19NCT05682599 · 300 enrolled · China

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Reverse transcriptase inhibitor; Replicase polyprotein 1ab inhibitor; Human immunodeficiency virus type 1 reverse transcriptase inhibitor”ChEMBL 37, by rule

Studies

All 2 Fosun Pharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05682599COVID-19 · China2UNKNOWNApr 15, 2023300
NCT05633433COVID-19 · Malaysia, Philippines3UNKNOWNJun 15, 20241,550

How it is read

Names in the registry

  • “Azvudine tablets(FNC) and Dolutegravir Sodium Tablets (DTG)”, 3 entries
  • “Azvudine tablets(FNC) and Itraconazole Capsules (ICZ)”, 3 entries
  • “Azvudine tablets(FNC) and Rifampicin Capsules (RIF)”, 3 entries
  • “Azvudine tablets”, 2 entries
  • “Azvudine tablets(FNC) and Rilpivirine Tablets (RPV)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.